Perrigo weakness creates buying opportunity, says Argus After Perrigo reported lower than expected Q3 EPS and reduced its guidance, Argus reports that the company's valuation are now in the lower portion of their historical levels. The firm cut its price target on the shares to $160 from $175 but it thinks the company has a number of positive catalysts and keeps a Buy rating.
Galmed and Perrigo sign agreement for aramchol API production Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.